Market Research Logo

The World Alzheimer's Disease Market (Incidence, Treatments, Key Companies, Pipeline and Trends)

Alzheimer’s Disease is the most common cause of dementia, constituting 60% to 70% of all cases, and the risk with the disease doubles every 5 years after age 65. Incidence of the disease is increasing, and the resulting attention given to Alzheimer's Disease has encouraged development of new treatments. There is an opportunity for pharmaceutical companies to compete in this market, as Kalorama analyst Melissa Elder outlines in this study.

This report includes incidence of Alzheimer’s disease worldwide with information for specific geographical regions; world demographics; life expectancy by country, and other general issues affecting the market.

Information is presented as a worldwide overview, with special emphasis on the U.S., Japan, Germany, and other key markets.

A market summary includes market analysis by products on the market and in development, in addition to a a regional market analysis, including:

  • US
  • Europe
  • Japan
  • Rest of World
as well as a competitive analysis of leading providers. Additionally key company profiles are included, with profiles of the following companies competing in this therapeutic area:
  • Eisai Co., Ltd.
  • Forest Laboratories
  • H. Lundbeck A/S
  • Johnson & Johnson
  • Merz Pharma GmbH
  • Novartis AG
  • Pfizer, Inc.
Markets are broken out by drug type:
  • Cholinesterase inhibitors
  • NMDA antagonists
as well as by product.

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information.

For the purpose of this study, Kalorama Information conducted interviews with more than 50 key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Additional interviews were completed with relevant company representatives including marketing directors, division managers, and product representatives.

All market data pertains to the world market at the manufacturers’ level. The base year for data was 2007. Historical data was provided for the years 2005 and 2006, with forecast data provided for 2008 through 2012. Compound annual growth rates (CAGRs) are provided for the 2005-2007 and 2008-2012 periods for each region and/or segment covered. Competitive analysis is provided for the year 2007.


  • Executive Summary
    • BACKGROUND
    • SCOPE AND METHODOLOGY
    • SIZE AND GROWTH OF THE MARKET
    • KEY ISSUES AND TRENDS AFFECTING MARKET
    • LEADING COMPETITORS
  • Introduction
    • OVERVIEW
    • STRUCTURAL ORGANIZATION OF THE NEUROLOGICAL SYSTEM
      • Central Nervous System
    • AGING AND ALZHEIMER'S DISEASE
    • STAGES OF ALZHEIMER'S DISEASE
      • Table Alzheimer's Disease Stages 1-7 and Descriptions
    • RISK FACTORS
    • LIFE EXPECTANCY AND THE GROWING INCIDENCE OF ALZHEIMER'S DISEASE
      • Table Average Life Expectancy in Years by Country 1980, 2004 and 2006 (years)
    • WORLD DEMOGRAPHICS
      • Table World Population by Selected Geographical Region, 2007 - 2050
      • Table Estimated World Population by Age and Geographical Region, 2007
      • Table Percent Population Over 65 by Year and Region
      • Table Estimated World Population by Age, 2007 and 2050
    • PREVALENCE,INCIDENCE AND MORTALITY
      • Table Estimated Prevalence, Incidence and Mortality for Alzheimer's Disease* by Region/Country, 2007
    • INSURANCE FOR THE ELDERLY IN THE UNITED STATES
      • Table Health Insurance Trends in the United States, Estimated 2007 (millions)
    • GENERIC COMPETITION
      • Teva/Mutual Pharmaceutical/United Research Laboratories and Eisai
      • Dr. Reddy's and Novartis
      • Ranbaxy and Ortho-McNeil Neurologics
  • Alzheimer's Disease Product Analysis
    • OVERVIEW OF PRODUCTS
      • Table Comparison of Marketed Alzheimer's Disease Treatments
    • ARICEPT
    • NAMENDA/EXIBA/AXURA
    • EXELON
    • RAZADYNE
    • OTHER PRODUCTS
  • Research and Development
    • OVERVIEW
      • Phase III
      • Phase II
      • Phase I
      • Preclinical Development
        • Table Alzheimer's Disease Therapies in Development
  • Market and Competitor Analysis
    • MARKET OVERVIEW
      • Table Alzheimer's Disease Market Analysis, 2005-2007 (in millions of dollars at the manufacturer's level)
      • Table Forecasted Alzheimer's Disease Market Analysis: 2008-2012 (in millions of dollars at the manufacturer's level)
      • Market Analysis by Product Type
        • Table Alzheimer's Disease Market Analysis by Drug Type, 2005-2007 (Cholinesterase inhibitors, NMDA antagonists) (in millions of dollars at the manufacturers' level)
        • Table Alzheimer's Disease Market Share by Drug Type, 2005
        • Table Alzheimer's Disease Market Share by Drug Type, 2007
      • Market Analysis by Country
        • Table Alzheimer's Disease Market Analysis by Region/Country, 2007
      • Competitive Analysis
        • Table Alzheimer's Disease Market Estimated Revenues and Market Share of Leading Suppliers 2007
      • Leading Products
        • Table Alzheimer's Disease Market Estimated Sales of Top Products 2007
  • Leading Manufacturers
    • OVERVIEW
    • EISAI CO., LTD.
      • Table Eisai's Net Revenues and R&D Expenses for 2006 and 2007 Millions
    • FOREST LABORATORIES
      • Table Forest's Net Revenues and R&D Expenses for 2006 and 2007 Millions
    • H. LUNDBECK A/S
      • Table Lundbeck's Net Revenues and R&D Expenses for 2006 and 2007 Millions
    • JOHNSON &JOHNSON
      • Table Johnson & Johnson's Net Revenues and R&D Expenses for 2006 and 2007 Millions
    • MERZ PHARMA GMBH
      • Table Merz Pharma's Net Revenues and R&D Expenses for 2006 and 2007 Millions
    • NOVARTIS AG
      • Table Novartis' Net Revenues and R&D Expenses for 2006 and 2007 Millions
    • PFIZER,INC.
      • Table Pfizer's Net Revenues and R&D Expenses for 2006 and 2007 Millions
  • List of Major Companies

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report